Rep. Daniel S. Goldman sold BioMarin Pharmaceutical (BMRN)
Rep. Daniel S. Goldman (D-NY-10) · $1K–$15K · traded Mar 6, 2023
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Mar 6, 2023
- Disclosed
- Apr 17, 2023
- Days to disclose
- 42
- Asset type
- Stock
- As filed
- BioMarin Pharmaceutical Inc.
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Goldman's trades →- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$50K–$100K
Sold VONOVIA SE ADR CMN (VONOY)
$50K–$100K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought VOLKSWAGEN AKTIENGESELLSCHAFT ADR CMN (VWAPY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Sold (partial) Vodafone Group Public Limited Company VOD
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought VAT GROUP AG ADR CMN (VACNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) UPM-KYMMENE OYJ ADR CMN (UPMMY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Swedbank AB (publ) SWDBY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Sumitomo Mitsui Financial Group SMFG
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold SOMPO JAPAN NIPPONKOA HLDGS IN ADR CMN (SMPNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) Shiseido Company, Limited SSDOY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought SALMAR ASA ADR CMN (SALRY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
Company context for BMRN
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
BMRN: third_quarter 2026 lobbying report
H.R.10571: SURGE TO SAVE NEWBORNS ACT; PROVISIONS RELATED TO NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARIFFS H.R.10359: PRIORITY FOR PEDIATRIC CURES ACT; PROVISIONS RELATED TO REMOVAL OF RARE PEDIATRIC PRIORITY REVIEW VOUCHERS SUNSET GENERAL DISCUSSIONS REGARDING CLINICAL TRIALS H.R. 1414: CAMERON'S LAW; ALL PROVISIONS DISCUSSIONS REGARDING INTELLECTU
Public: Oct 20, 2026, 4:44 PM EDTOriginal source ↗BMRN: third_quarter 2026 lobbying report
Provide strategic counsel and advocacy on issues relating to biopharmaceuticals for rare diseases driven by genetic causes generally, or BioMarin Pharmaceutical specifically.
Public: Oct 20, 2026, 1:22 PM EDTOriginal source ↗BMRN: second_quarter 2026 lobbying report
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT GENERAL DISCUSSIONS REGARDING TARDE GENERAL DISCUSSIONS REGARDING CLI
Public: Jul 20, 2026, 5:14 PM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.